摘要
目的制备醋酸地塞米松缓释微球并进行体内外评价及生物相容性考察。方法采用乳化-溶剂挥发法制备微球,并以形态、粒径、载药量、包封率及体外释放为指标对其进行体外评价,同时探讨其体外释药机制;测定皮下注射微球后体内血药浓度,考察微球的体内释放情况;通过考察关节腔注射微球后的组织变化评价微球的组织相容性。结果微球平均粒径小于10μm,包封率高于90%,突释小于7%,体内外均可持续释放一个月左右,且重现性试验中各指标的RSD值均小于3·75%;关节腔注射微球后16d内未见炎症发生,说明微球的组织相容性好。结论本实验所制微球各方面性质均较好,适合关节腔注射。
Abstract
OBJECTIVE To prepare PLGA microspheres containing dexamethasone acetate and evaluate their characteristics and biocompatibility. METHODS The microspheres were prepared by solvent evaporation method, and were evaluated in vitro by responses such as morphology, particle size, encapsulation, drug loading, burst effect and in vitro release.With dexamethasone acetate suspension as reference standard, the release of the microspheres in vivo was evaluated. The biocompatibility of the microspheres was also investigated. RESULTS The encapsulation of microspheres was higher than 90%, with the burst release lower than 7% and the particle size was smaller than 10 μm. The release of microspheres lasted about one month both in vitro and in vivo while the relative bioavailability was higher than 100%. The RSDs of all respones were smaller than 3.75%, and there were no inflammatory responses observed during the experiment. CONCLUSION Microspheres are suitable for intra-articular administration.
关键词
醋酸地塞米松 /
聚乳酸-羟基乙酸 /
微球 /
乳化-溶剂挥发法
{{custom_keyword}} /
Key words
dexamethasone acetate /
PLGA /
microspheres /
emulsion-solvent evaporation
{{custom_keyword}} /
李志平;刘燕;梅兴国.
注射用醋酸地塞米松缓释微球体内外评价及生物相容性考察[J]. 中国药学杂志, 2006, 41(17): 1320-1323
LI Zhi-ping;LIU Yn;MEI Xing-guo.
Investigation on in vitro and in vivo Characteristics and Biocompatibility of Dexamethasone acetate-PLGA Microspheres for Injection [J]. Chinese Pharmaceutical Journal, 2006, 41(17): 1320-1323
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SUN Y. Pratical Diagnostics and Therapeutics of Arthritis（实用关节炎诊断治疗学）[M] . Beijing. The Medical Publishing Company of Beijing University，2002：105-107.
[2] SHAW I H，KNIGHT C G，PAGE T D P，et al. Liposome incorporated corticosteroids： I. The interaction of liposomal cortisol palmitate with inflammatory synovial membrane[J] . Br J Exp Pathol，1979，60：142-150.
[3] HICKEY T，KREUTZER D，BURGESS D J. Dexamethasone/PLGA microspheres for continuous delivery of an anti-infammatory drug for implantable medical devices[J] . Biomaterials，2002，23： 1649-1656.
[4] HICKEY I，KREUTZER L，BURGESS D J，et al. In vivo evaluation of a dexamenthasone/ PLGA microsphere system designed to suppress the inflammatory tissue response to implatable medicaldevices[J] . Wiley Periodicals，2002：180-187.
[5] SUZUKI，MAKOTO，ISHIGAKI，et al. Intra-articular preparation for the treatment of arthropathy[P] . United States Patent，6，428，804. 2002-08-06.
[6] WU W，LU B. Determination of 5-fluorouracil or dexamethasone in PLA microspheres by first-order derivative spectrophotometry[J] .China Pharmacist(中国药师)，1999，2(2)： 57-59.
[7] Ch.P（2000） Vol Ⅱ（中国药典2000年版. 二部）[S] .2000：1075-1076.
[8] ROSHOL H，SKREDE K K，ERO C E. Dexamethasone and methylprednisolone affect rat peritoneal phagocyte chemiluminescence after administration in vivo[J] .Eur J Pharmacology，1995，286：9-17.
[9] AHSAN F，RIVAS I P，KHAN M A，et al. Targeting to macrophages：role of physicochemical properties of particulate carriers-liposomes and microspheres on the phagocytosis by macrophages[J] .J Controlled Release，2002，79：29-40.
[10] YAMAMOTO N，FUKAI F，OHSHIMA H. Dependence of the phagocytic uptake of polystyrene microspheres by differentiated HL60 upon the size and surface properties of the microspheres[J] .Colloids Surf B Biointerfaces，2002，25：157-162.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
